EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Circulating Oxylipins Predict Mortality in Heart Failure with Preserved Ejection Fraction

Vaishnavi Aradhyula, Sareeta Manandhar, Alborz Sherafati, Alex Kloster, Anas Fares, Prabhatchandra Dube, Pamela S Brewster, George V Moukarbel, Krishna Rao Maddipati, Steven T Haller, David J Kennedy, Rajesh Gupta und 1 weitere

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15425 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Vaishnavi Aradhyula und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA. Hauptthemen laut MEDLINE: Dinoprost, Heart Failure, Diastolic, Oxylipins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Toledo Women and Philanthropy Genetic Analysis Instrumentation Center, NIH HHS, David and Helen Boone Foundation Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure with preserved ejection fraction (HFpEF) poses significant diagnostic, prognostic and therapeutic challenges, with high morbidity and mortality rates. Currently, there are limited predictors of outcomes in HFpEF patients. Circulating oxidized polyunsaturated fatty acyl lipids, or oxylipins, are known to initiate and resolve inflammation in cardiovascular diseases. However, their ability to predict mortality in HFpEF has not been established. We hypothesize that a panel of oxylipins can predict and stratify mortality risk in HFpEF patients. Methods and results Venous and arterial blood samples were collected during right heart catheterization from 90 HFpEF patients at a single institution. Patients were followed for 5 years to determine morbidity and mortality rates. We measured 143 arterial and 143 venous oxylipins in all study participants using liquid chromatography-mass spectrometry. Volcano plots were used to visualize differences in oxylipins between survived and deceased groups. Receiver operator characteristic (ROC) curves were used to determine optimal biomarker cut-points, and the relationship between the most significant oxylipins and mortality was assessed with Kaplan–Meier (KM) curves. HFpEF patients with 5-year mortality had increased age, decreased body mass index, decreased diastolic blood pressure and worse renal function at baseline. They also had more severe pulmonary hypertension (PH) and right heart dysfunction. Volcano plot analysis revealed that arterial oxylipin 15-keto prostaglandin F2a (PGF2a) was significantly associated with 5-year mortality. ROC curve analysis identified an optimal cut-point for 15-keto PGF2a, and participants with elevated arterial 15-keto PGF2a had significantly increased 5-year mortality on KM curves. Multivariable adjusted analysis identified 15-keto PGF2a as a significant predictor of 5-year mortality (OR 1.82; CI 1.03, 3.5).

Conclusions

In this cohort of patients with HFpEF, arterial 15-keto PGF2a, a stable metabolite of PGF2a, significantly predicted 5-year mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DinoprostHeart Failure, DiastolicOxylipinsAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkersCardiac CatheterizationEchocardiographyProspective StudiesOhioPrognosis

Stichwörter der Autor:innen

Diastolic dysfunctionHFpEFLipidomicsOxylipinsPUFA

Substanzen

15-ketoprostaglandin F2alphaBiomarkersDinoprostOxylipins

Autor:innen und Institutionen

  • Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
  • Department of Pathology, Lipidomic Core Facility, Wayne State University, Detroit, Michigan, USA.

Förderung

  • University of Toledo Women and Philanthropy Genetic Analysis Instrumentation Center
  • NIH HHS
  • David and Helen Boone Foundation Research Fund
  • Adela and Alfred Mundt Foundation for Heart Failure Research
  • NHLBI NIH HHS
  • NCRR NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health

Zitieren

APA

Aradhyula, V., Manandhar, S., Sherafati, A., Kloster, A., Fares, A., Dube, P., Brewster, P. S., Moukarbel, G. V., Maddipati, K. R., Haller, S. T., Kennedy, D. J., Gupta, R., & Khouri, S. J. (2025). Circulating Oxylipins Predict Mortality in Heart Failure with Preserved Ejection Fraction. ESC Heart Failure. https://doi.org/10.1002/ehf2.15425

Vancouver

Aradhyula V, Manandhar S, Sherafati A, Kloster A, Fares A, Dube P, et al. Circulating Oxylipins Predict Mortality in Heart Failure with Preserved Ejection Fraction. ESC Heart Failure. 2025. doi:10.1002/ehf2.15425

BibTeX
@article{Aradhyula2025,
  author = {Aradhyula, Vaishnavi and Manandhar, Sareeta and Sherafati, Alborz and Kloster, Alex and Fares, Anas and Dube, Prabhatchandra and Brewster, Pamela S and Moukarbel, George V and Maddipati, Krishna Rao and Haller, Steven T and Kennedy, David J and Gupta, Rajesh and Khouri, Samer J},
  title = {Circulating Oxylipins Predict Mortality in Heart Failure with Preserved Ejection Fraction},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15425}
}
Kostenlos starten →